BioVision, Inc. Aquires BioVisioN AG To Develop Disease Management Solutions
Published: Feb 27, 2006
CANTON, Mass., Feb. 27 /PRNewswire/ -- Digilab LLC, a global leader in molecular spectroscopy systems and solutions, today announced the acquisition of BioVisioN GmbH, known for pioneering Peptidomics(R), a comprehensive analytical peptide profiling and discovery technology for the development of novel substances and methods used to diagnose and treat human diseases. The acquisition accelerates Digilab's global reach into life science research and bio-analytical services markets.
"The acquisition of BioVisioN is one of several initiatives designed to assure our customers and partners that Digilab remains committed to its global vision to be 'Spectroscopy's Leading Light,'" said Digilab Chairman and CEO Sidney Braginsky. "Moving forward, we plan to expand our product line to bring innovative and proprietary tools to the life sciences and bio-analytical research markets."
The acquisition comes one year after Digilab sold its Fourier-Transform InfraRed (FTIR) molecular spectroscopy assets to Varian, Inc. Since then, Digilab has focused on re-entering the market with pre-analytical sample prep, bioinformatics and detection/analysis tools designed for research and diagnostics molecular spectroscopy applications. These tools will connect Digilab to disease management-focused on in-vitro diagnostics products designed for time critical information delivery at the point of care.
BioVisioN is a leader in proprietary bioinformatics tools used to qualify, quantify and sequence diagnostic and therapeutic biomarkers needed to support pharmacogenomics approaches to personalized medicine. Known as the "Peptidomics" company for the discovery power of its patented Differential Peptide Display (DPD) bioinformatics software, BioVisioN works with leading life science companies to facilitate their peptide biomarker diagnostic and therapeutic discovery needs.
"We plan to integrate proprietary Digilab tools into research processes and ultimately disease management systems which establish new standards of care," said Digilab President and COO David T. Giddings. "Our customers unmet needs for sample prep and information detection and analysis will be addressed by Digilab products that are designed for ease of use and cost effectiveness."
About Digilab LLC
As a global leader in molecular spectroscopy systems for almost 40 years, Digilab (www.digilabglobal.com) develops innovative and differentiated applications for the life sciences research and in-vitro diagnostics markets including pharmaceutical and biotech industries as well as universities and the U.S. government. The company's pioneering work for the U.S. Government in 1969 led to the development, manufacture, sales and service of the first commercial Fourier-Transform InfraRed (FTIR) spectrometer. In the fall of 2004, Digilab sold its FTIR molecular spectroscopy assets to Varian Inc. Since then, the company has remained focused on sample prep, bioinformatics and detection/analysis tools offering solutions for research and diagnostics applications featuring molecular spectroscopy methods.
Located in Hannover, Germany, BioVisioN has developed and patented internationally unique Peptidomics(R) technologies while generating proprietary bioinformatics tools in the process. BioVisioN works with companies from the pharmaceutical and diagnostics sectors, technology hardware and software suppliers and academic institutions. In 1997, BioVisioN ( http://www.biovision-discovery.de/set_all.htm ) spun-off the "Institut fur Peptidforschung" (IPF), a public institute for peptide research, with the vision of making a contribution to health care by discovering and developing novel substances and methods to diagnose and treat human diseases. BioVisioN has worked to discover new biomarkers or drug targets with such companies as Astra Zeneca, Merck & Co, Novartis, Novo Nordisk, Roche Diagnostics, Abbott Laboratories and Solvay Pharmaceuticals.Digilab LLC
CONTACT: Joseph Griffin, CFO of Digilab LLC, +1-781-575-0264, firstname.lastname@example.org